Royalty Pharma plc announced on July 17, 2025, the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. These appointments aim to strengthen the board with diverse expertise in the biopharmaceutical and finance industries.
Carole Ho serves as Chief Medical Officer and Head of Development at Denali Therapeutics, bringing 20 years of experience in biopharma, including leadership in therapeutic development from early to late stages. Elizabeth Weatherman is a Special Limited Partner at Warburg Pincus LLC, a global private equity firm, and has 35 years of experience as an investor across the healthcare industry.
The addition of Ms. Ho and Ms. Weatherman is expected to provide invaluable leadership and insights as Royalty Pharma executes its long-term strategy. Their combined experience in medical innovation, capital markets, and corporate governance will support the company's continued growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.